# A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct07287150/  
OnCo record `nct07287150` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Inavolisib, Enzalutamide, Abiraterone acetate in prostate cancer, run by Hoffmann-La Roche, now recruiting.

## Summary

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT07287150 by Hoffmann-La Roche, with 100 participants planned, started 2026-03-11 and due to reach its primary completion in 2028-03-31. Interventions recorded: Inavolisib, Enzalutamide, Abiraterone, Docetaxel. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07287150
- Phase: 2
- Setting: A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Hoffmann-La Roche
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07287150: https://clinicaltrials.gov/study/NCT07287150

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Inavolisib](https://onco.cc/drugs/inavolisib/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct07287150.json